1st International mRNA Health Conference in Tubingen
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Tübingen, Germany, 15 Aug. 2013 -- The 1st International mRNA Health Conference, taking place on Oct. 23 and 24, will be the first forum of its kind to host the world’s experts in mRNA. With this event, the conference organizers, which include the University of Tübingen, the University Hospital of Tübingen and the Tübingen-based biotechnology company CureVac, are laying the foundation for a new biotechnological sector: mRNA-based therapeutics. The conference is intended to become an annual event.
Medically used messenger RNA (mRNA) is currently evolving into a hotspot in research and development in biotechnology. A few years ago, the medical use of mRNA seemed almost out of reach. However, obstacles, such as the instability of the molecule, have now been overcome, and today, scientists around the world are developing drugs based on this highly potent biomolecule. The first clinical studies are currently ongoing, and innovative therapeutic treatment options for numerous diseases such as cancer, cardiovascular diseases or influenza are becoming more feasible. In October, experts in mRNA from academia and industry will present their latest study data to an expert audience, and a discussion of the medical potential of mRNA will follow.
The conference organizers, Michael Kormann, Ph.D., University of Tübingen, and Ingmar Hoerr, Ph.D., chief executive officer, CureVac, emphasize the special relevance of Tübingen to this event noting that nucleic acids, including RNA, were discovered here more than 140 years ago.
Further information about the 1st international mRNA Health Conference can be found under: http://www.mrna-conference.com
Contact:
Jun.-Prof. Dr. rer. nat. Michael Kormann
Universitätsklinik für Kinder- und Jugendmedizin (Abt. I)
Sektion Pädiatrische Infektiologie & Immunologie
AG Translationale Genomik und Gentherapie in der Pädiatrie
Wilhelmstr. 31
72074 Tübingen, Germany
Tel.: +49(0)7071/29-84305
Fax: +49(0)7071/29-4717
michael.kormann@med.uni-tuebingen.de
Verena Lauterbach
Manager Communications
CureVac GmbH, Tübingen, Germany
Tel.: +49(0)7071/92053-756
verena.lauterbach@curevac.com
Martina Schwarzkopf, Ph.D.
Account Supervisor
Russo Partners, LLC
12 West 27th Street, 4th Floor
New York, NY 10001
T (212) 845-4292
M (347) 591 8785
F (212) 845-4260
martina.schwarzkopf@russopartnersllc.com
www.russopartnersllc.com
Visit our blog at www.rxforpr.com.
Follow our agency and client news on Twitter. Sign up at www.twitter.com/russopartners
Help employers find you! Check out all the jobs and post your resume.
Tübingen, Germany, 15 Aug. 2013 -- The 1st International mRNA Health Conference, taking place on Oct. 23 and 24, will be the first forum of its kind to host the world’s experts in mRNA. With this event, the conference organizers, which include the University of Tübingen, the University Hospital of Tübingen and the Tübingen-based biotechnology company CureVac, are laying the foundation for a new biotechnological sector: mRNA-based therapeutics. The conference is intended to become an annual event.
Medically used messenger RNA (mRNA) is currently evolving into a hotspot in research and development in biotechnology. A few years ago, the medical use of mRNA seemed almost out of reach. However, obstacles, such as the instability of the molecule, have now been overcome, and today, scientists around the world are developing drugs based on this highly potent biomolecule. The first clinical studies are currently ongoing, and innovative therapeutic treatment options for numerous diseases such as cancer, cardiovascular diseases or influenza are becoming more feasible. In October, experts in mRNA from academia and industry will present their latest study data to an expert audience, and a discussion of the medical potential of mRNA will follow.
The conference organizers, Michael Kormann, Ph.D., University of Tübingen, and Ingmar Hoerr, Ph.D., chief executive officer, CureVac, emphasize the special relevance of Tübingen to this event noting that nucleic acids, including RNA, were discovered here more than 140 years ago.
Further information about the 1st international mRNA Health Conference can be found under: http://www.mrna-conference.com
Contact:
Jun.-Prof. Dr. rer. nat. Michael Kormann
Universitätsklinik für Kinder- und Jugendmedizin (Abt. I)
Sektion Pädiatrische Infektiologie & Immunologie
AG Translationale Genomik und Gentherapie in der Pädiatrie
Wilhelmstr. 31
72074 Tübingen, Germany
Tel.: +49(0)7071/29-84305
Fax: +49(0)7071/29-4717
michael.kormann@med.uni-tuebingen.de
Verena Lauterbach
Manager Communications
CureVac GmbH, Tübingen, Germany
Tel.: +49(0)7071/92053-756
verena.lauterbach@curevac.com
Martina Schwarzkopf, Ph.D.
Account Supervisor
Russo Partners, LLC
12 West 27th Street, 4th Floor
New York, NY 10001
T (212) 845-4292
M (347) 591 8785
F (212) 845-4260
martina.schwarzkopf@russopartnersllc.com
www.russopartnersllc.com
Visit our blog at www.rxforpr.com.
Follow our agency and client news on Twitter. Sign up at www.twitter.com/russopartners
Help employers find you! Check out all the jobs and post your resume.